Glutathione

Overview

Glutathione (GSH, gamma-L-glutamyl-L-cysteinyl-glycine) is a tripeptide present in virtually all eukaryotic cells, making it the most abundant non-protein thiol compound in mammalian biology. It serves as the principal intracellular antioxidant, the central cofactor in phase II xenobiotic detoxification, and a critical regulator of cellular redox homeostasis. Intracellular glutathione concentrations typically range from 1-10 mM, with the highest levels found in the liver (5-10 mM), the primary organ of detoxification.

Glutathione exists in two forms: the reduced thiol form (GSH, which is biologically active) and the oxidized disulfide form (GSSG, glutathione disulfide). Under normal physiological conditions, the GSH:GSSG ratio exceeds 100:1, and deviations from this ratio serve as sensitive indicators of oxidative stress. The enzyme glutathione reductase, using NADPH as an electron donor, continuously regenerates GSH from GSSG, maintaining the reducing intracellular environment essential for protein function and cell survival.

Glutathione's importance extends beyond simple antioxidant chemistry. It participates in amino acid transport (the gamma-glutamyl cycle), serves as a reservoir for cysteine, regulates nitric oxide bioavailability, modulates immune function, and influences gene expression through redox-sensitive transcription factors. Depletion of glutathione is associated with a wide range of pathological conditions including neurodegenerative diseases, liver disease, pulmonary fibrosis, HIV/AIDS progression, and aging.

The compound is widely available as a dietary supplement in oral, sublingual, liposomal, and intravenous formulations, with applications ranging from general antioxidant support to skin lightening — the latter use driven by glutathione's inhibition of melanin synthesis.

Structure and Sequence

Chemical structure: Gamma-L-glutamyl-L-cysteinyl-glycine

• Molecular formula: C₁₀H₁₇N₃O₆S
• Molecular weight: 307.32 g/mol
• Key structural features:
  • Gamma-peptide bond: The glutamate residue is linked through its gamma-carboxyl group (side chain) rather than the alpha-carboxyl group, creating an unusual isopeptide bond that renders glutathione resistant to degradation by most intracellular peptidases
  • Cysteine thiol group: The sulfhydryl (-SH) group of the central cysteine residue is the chemically active site, serving as an electron donor for reduction reactions
  • Glycine C-terminus: Protects the cysteine residue from intracellular cleavage by gamma-glutamyl cyclotransferase

Biosynthesis (two-step enzymatic process):

1. Gamma-glutamylcysteine ligase (GCL): Catalyzes the formation of the gamma-peptide bond between glutamate and cysteine — this is the rate-limiting step, subject to feedback inhibition by GSH
2. Glutathione synthetase: Adds glycine to the C-terminus, completing the tripeptide

Cysteine as the rate-limiting substrate: Intracellular cysteine availability limits glutathione synthesis. This has driven interest in cysteine donors such as N-acetylcysteine (NAC) and whey protein as strategies to support GSH levels.

Mechanism of Action

Direct Antioxidant Activity

The cysteine thiol group of GSH directly reduces reactive oxygen species (ROS) and reactive nitrogen species (RNS):

• Hydrogen peroxide detoxification: GSH serves as the electron donor for glutathione peroxidase (GPx) enzymes, converting H₂O₂ to water. This is the primary enzymatic pathway for H₂O₂ removal in most cell types.
• Lipid hydroperoxide reduction: GPx4 (phospholipid hydroperoxide glutathione peroxidase) uses GSH to reduce lipid peroxides within membranes, protecting against ferroptosis
• Superoxide and hydroxyl radical scavenging: Non-enzymatic direct reaction with highly reactive oxygen species
• Peroxynitrite detoxification: GSH reacts with peroxynitrite, preventing nitration of tyrosine residues on proteins

Phase II Conjugation (Detoxification)

Glutathione S-transferases (GSTs) catalyze the conjugation of GSH with electrophilic xenobiotics and endogenous reactive compounds:

• Xenobiotic metabolism: GSH conjugation renders hydrophobic toxins, drug metabolites, and environmental chemicals water-soluble for renal or biliary excretion
• Endogenous detoxification: Conjugation with reactive aldehydes (4-hydroxynonenal, malondialdehyde), epoxides, and quinones
• Mercapturic acid pathway: GSH conjugates are sequentially processed to cysteine conjugates and then N-acetylated to form mercapturic acids for urinary excretion

Protein Thiol Regulation (S-Glutathionylation)

GSH participates in reversible S-glutathionylation of protein cysteine residues, a post-translational modification that:

• Protects critical protein thiols from irreversible oxidation
• Regulates enzyme activity (e.g., glyceraldehyde-3-phosphate dehydrogenase, protein tyrosine phosphatases)
• Modulates redox-sensitive signaling pathways (NF-kB, Nrf2, AP-1)

Melanin Synthesis Inhibition

Glutathione inhibits melanogenesis through multiple mechanisms:

• Binding to the active site of tyrosinase, the rate-limiting enzyme in melanin synthesis
• Shifting melanin synthesis from dark eumelanin toward lighter pheomelanin by providing cysteine for cysteinyl-DOPA formation
• Antioxidant-mediated reduction of oxidative stress that stimulates melanogenesis

Research Summary

Pharmacokinetics

• Oral bioavailability: Poor for standard oral GSH formulations; significant first-pass hydrolysis by gamma-glutamyltransferase in the intestinal epithelium and hepatic extraction
• Liposomal formulation: Improved absorption through phospholipid encapsulation; studies show 30-100% greater plasma elevation vs. unencapsulated GSH
• Sublingual delivery: Bypasses first-pass metabolism; produces measurable plasma increases
• Intravenous administration: Achieves immediate supraphysiological plasma levels; half-life in plasma is approximately 10-15 minutes due to rapid cellular uptake and extracellular degradation
• Intracellular half-life: Variable by tissue type; hepatic GSH turns over with a half-life of approximately 2-3 hours
• Gamma-glutamyl cycle: Extracellular GSH is broken down by gamma-glutamyltransferase on cell surfaces; the resulting amino acids are taken up and used for intracellular GSH resynthesis (the "salvage" pathway)
• Precursor strategies: NAC (N-acetylcysteine, typically 600-1800 mg/day) and GlyNAC (glycine + NAC) are commonly used to support endogenous GSH synthesis rather than supplementing GSH directly
• Dietary sources: Sulfur-rich foods (cruciferous vegetables, alliums, whey protein) support GSH synthesis by providing cysteine

Dosing Protocols

The following dosing information is compiled from published research and community discussion for educational purposes only. No FDA-approved human dosing guidelines exist for most research peptides. Always consult a qualified healthcare professional.

Reconstitution

Dosing Schedule

Syringe Measurements (U-100 insulin syringe)

Cycle Guidelines

• Cycle length: 4-8 weeks, with optional 2-4 weeks off between cycles
• Route: Subcutaneous injection
• Timing: Consistent daily timing
• Injection sites: Rotate between abdomen, thighs, and upper arms

Common Discussion Topics

Oral glutathione absorption debate: The bioavailability of oral glutathione remains contentious. Traditional pharmacological understanding held that oral GSH was completely hydrolyzed before reaching the systemic circulation. More recent studies using reduced GSH, liposomal formulations, or sublingual delivery have demonstrated measurable plasma elevations, though whether these translate to meaningful intracellular repletion remains debated.

NAC vs. direct glutathione supplementation: N-acetylcysteine is the most extensively studied strategy for boosting intracellular GSH. NAC provides cysteine (the rate-limiting substrate) after hepatic deacetylation, effectively supporting GSH synthesis from within the cell. Proponents of direct GSH supplementation argue it bypasses the need for intact biosynthetic machinery, which may be compromised in disease states.

Skin lightening applications: Glutathione's depigmenting effects have driven enormous demand, particularly in parts of Asia. Both oral and intravenous formulations are marketed for skin lightening, though dermatological societies have raised concerns about unregulated IV glutathione clinics and the lack of long-term safety data for cosmetic IV use.

Glutathione depletion in disease: Reduced GSH levels are observed in virtually every chronic disease state studied, from neurodegeneration to liver disease to cancer. The central question is whether GSH depletion is a cause, consequence, or both — a distinction that determines the therapeutic potential of GSH repletion.

GlyNAC (glycine + NAC) protocol: Emerging research suggests that combining glycine with NAC (providing both cysteine and glycine substrates simultaneously) more effectively restores GSH levels and improves biomarkers of oxidative stress, mitochondrial function, and aging compared to either amino acid alone.

Related Compounds

• Carnosine — dipeptide antioxidant with complementary anti-glycation and pH buffering functions
• GHK-Cu — copper-binding peptide with antioxidant gene expression modulating activity